News

Read more

TargED Secures €21.5 Million Series A Extension, Total Funding Now Over €60 Million

December 16, 2025
Read more

TargED Presents Positive Clinical Results for TGD001 from Phase 1 Study During Oral Session at ASH 2025

December 8, 2025
Read more

TargED to Present First Clinical and New Preclinical Data on TGD001 at ASH 2025

November 3, 2025
Read more

Samuel White joins TargED as Chief Business Officer

July 1, 2025
Read more

TargED Secures EIC Accelerator Grant

June 30, 2025
Read more

Filip Van den Wyngaert joins TargED as Vice President Asset Management

April 28, 2025
Read more

TGD001 receives Orphan Drug Designation in the United States of America

March 24, 2025
Read more

TargED enters clinic with Phase 1 trial of its groundbreaking thrombolytic TGD001

December 19, 2024
Read more

Anne-Grethe Mortensen joins TargED as Non-Executive Board Member

November 14, 2024
Read more

TGD001 receives Orphan Drug Designation in Europe

July 29, 2024
Read more

Dr. Anja Harmeier as Supervisory Board Member

September 5, 2023
Read more

Key Appointments Management Team

May 2, 2023
Read more

Appointed – Erik van den Berg as Chair of Board

January 19, 2023
Read more

Appointed – Scientific Advisory Board AIS

September 16, 2022
Read more

Microlyse as treatment for AIS published in Blood journal

August 17, 2022
Read more

Microlyse as treatment for TTP published in Blood journal

February 19, 2022
Read more

TargED raises €39 million in a series A investment round

February 19, 2022
Read more

TargED is granted the NWO Take Off II loan

December 18, 2020
Read more

TargED closes €1.35m seed investment round!

November 30, 2020
Read more

FOUNDED

July 7, 2020